期刊文献+

TRACP-5b、β_2MG在多发性骨髓瘤患者血清中的表达及意义

下载PDF
导出
摘要 目的探讨抗酒石酸酸性磷酸酶5b(TRACP-5b)、β2微球蛋白(β2MG)在多发性骨髓瘤(MM)患者血清中的表达及意义。方法采用ELISA法检测20例MM患者(观察组)治疗前后及20例健康体检者(对照组)血清TRACP-5b、β2MG水平,分析两指标间相关性。结果观察组TRACP-5b、β2MG水平随骨损程度加重而升高,P均<0.05。观察组治疗后及对照组TRACP-5b、β2MG水平均明显低于观察组治疗前,观察组治疗后β2MG水平明显高于对照组,P均<0.05。结论血清TRACP-5b、β2MG水平检测对于早期发现、病情及预后评估具有重要意义。
出处 《山东医药》 CAS 北大核心 2011年第47期79-80,共2页 Shandong Medical Journal
  • 相关文献

参考文献6

  • 1Alexandrakis MG, Passam FH, Sfiridaki A, et al. Elevated serum concentration of hepatocyte growth factor in patients with multiple myeloma: correlation with markers of disease activity[ J]. Am J Hematol, 2003,72(4) :229-233.
  • 2曾芳馨,熊中云.抗酒石酸酸性磷酸酶与骨代谢[J].华西医学,2005,20(3):545-545. 被引量:8
  • 3Mlexandrakwas MG, Rassam FH, Ganotakwas ES, et al. The Clinical and prognostic significance of erythrocyte sedimentation rate (ESR) , serum interleukin-6 ( IL-6 ) and acute phase protein levels in multiple myeloma[ J ]. Clin Lab Haematil, 2003,25 (1) :41-46.
  • 4关晶,付蓉,阮二宝,王晓明,王国锦,梁勇,瞿文,宋嘉,刘鸿,吴玉红,王化泉,邢莉民,李丽娟,邵宗鸿.84例多发性骨髓瘤骨病发病及其相关因素研究[J].中国肿瘤临床,2008,35(3):135-138. 被引量:8
  • 5Terpos E, de la Fuente J, Szydlo R, et al. Tartrate-resistant acid phosphatase isoform 5b: a novel serum marker for monitoring bone disease in multiple myeloma[ J ]. Int J Cancer, 2003,106 (3) :455- 457.
  • 6Weber DM, Wang M, Delassll EK. Confirmation of prognostic value of model using B2 Microglobulin(B2-M) and album in for multiple myeloma (MM)proposed by the International Myeloma Working Group(IMWG) with similar results using B2-M alone [ J ]. Blood, 2003,102( 11 ) :937-951.

二级参考文献13

  • 1李征洋,侯健.骨髓瘤患者经白蛋白校正后血钙浓度分析[J].武警医学,2004,15(9):672-675. 被引量:2
  • 2吕晓芳,于世英,冷彦.骨代谢生化指标在恶性肿瘤骨转移诊断中的价值[J].中国肿瘤临床,2007,34(3):154-156. 被引量:12
  • 3Janckila AJ,Takahashi K,Sun SZ,et al.Tartrate-resistant acid phosphatase isoform 5b as serum marker for osteoclastic activity[J].Clin Chem,2001,47(1):74-80.
  • 4Halleen JM,Alatalo SL,Janckila AJ,et al.Serum tartrate-resistant acid phosphatase 5b is a specific and sensitive marker of bone resorption[J].Clin Chem,2001,47(3):597-600.
  • 5Alatalo SL,Ivaska KK,Waguespack SG,et al.Osteoclast-derived serum tartrate-resistant acid phosphatase 5b in Albers-Schonberg disease(type Ⅱ autosomal dominant osteopetrosis)[J].Clin Chem,2004,50(5):883-90.
  • 6Hoffman R. Hematology-basic principles and practice[M]. 3^rd edition.北京:北京大学医学出版社.1998.1403-1410
  • 7Terpos E, Dimopoulos MA. Myeloma bone disease: pathophysiology and management[J]. Ann Oncol, 2005, 16(8): 1223-1231
  • 8Yeh HS, Berenson JR. Myeloma bone disease and treatment options[J]. EurJ Cancer, 2006, 42: 1554-1563
  • 9Abe M, Hiura K, Wilde J, et al. Role for macrophage inflammatory protein (MIP)-1 alpha and MIP-1 beta in the development of osteolytic lesions in multiple mydoma [J].Blood, 2002, 100(6): 2195 -2202
  • 10Kyle RA, Gertz MA, Witzig TE, et al. Review of 1027 patient s with newly diagnosed multiple myeloma [J]. Mayo Clin Proc, 2003, 78(1): 21-33

共引文献14

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部